Compare Eli Lilly And Co (LLY) vs US Bancorp (USB) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

U.S. Bancorp (USB) trades at $63.09, down 0.08% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $69.70. Recent Q2 2026 earnings beat expectations with EPS of $1.35, driven by loan growth and fee income. Revenue reached a record $28.54B in 2025, with net income margin improving to 27.61%. The stock shows strong institutional support with 47.92% of analysts rating it a Buy.

Outlook remains positive due to earnings momentum and dividend yield near 3%, but risks include rising debt-to-asset ratios and macroeconomic sensitivity. Upside potential exists if loan growth and digital banking adoption continue, though investor caution is warranted given RSI levels indicating mild overbought conditions.